

## Cynata Adds New Site for MEND Clinical Trial

**Melbourne, Australia; 30 May 2022:** Cynata Therapeutics Limited (ASX: “CYP” or “Cynata”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that St George Hospital in Sydney is now a participating site and is seeking to recruit patients in the MEND clinical trial (a pilot, open-label, randomised controlled clinical trial to investigate early efficacy of CYP-001 in adults admitted to intensive care with respiratory failure), thereby accelerating the recruitment process.

**Dr Jolanta Airey, Cynata’s Chief Medical Officer, said:**

*“We are very pleased St George Hospital is now participating in the MEND trial. We passed the half-way point in the trial several months ago but we are also taking additional steps to further increase the pool of potential subjects despite continued challenges faced by the hospital system. We expect that the addition of this large teaching hospital will accelerate active participation of trial subjects and provide greater assurance toward timely completion later this year.”*

The St George Hospital and Health Services is part of the South Eastern Sydney Local Health District. It is an accredited, principal teaching hospital of the University of New South Wales and, with around 550 beds, is the largest hospital within the Local Health District and among the leading centres for trauma and emergency management in the State.

As advised in an announcement dated 29 March 2021, the MEND trial aims to recruit 24 adult patients admitted to intensive care with respiratory failure who will be randomly assigned to receive standard care or Cynata’s novel Cymerus™ mesenchymal stem cell (MSC) product CYP-001 plus standard care.

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

**CONTACTS:** Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119 343, [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Lauren Nowak, Media Contact, +61 (0)400 434 299, [laurenmaree@live.com.au](mailto:laurenmaree@live.com.au)

**About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Planning for a Phase 2 clinical trial in GvHD is presently underway. Clinical trials of Cymerus products in osteoarthritis (Phase 3), respiratory failure and diabetic foot ulcers (DFU) are currently ongoing. In addition, Cynata has demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

**Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.**